Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Phase Ib open-label study to evaluate safety, tolerability, immunogenicity, and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC; OBERTO-201).
Authors
Joleen M. Hubbard
Mayo Clinic Rochester, Rochester, MN;
Joleen M. Hubbard , Tyler J. Zemla , Rondell P. Graham , Zhaohui Jin , Mojun Zhu , Jessica L. Mitchell , Elise Novo , Eva Vegh , Orsolya Lorincz , Mariann Kremlitzka , Eszter Somogyi , Levente Molnar , József Tóth , Eniko Rita Toke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05130060
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 147)
DOI
10.1200/JCO.2023.41.4_suppl.147
Abstract #
147
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study.
First Author: Yu Yao
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results.
First Author: Shubham Pant
Poster
2022 ASCO Annual Meeting
Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, single-arm, open-label study.
First Author: Shiman Wu
Poster
2017 ASCO Annual Meeting
Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.
First Author: Jason Alan Chesney